Description and Brand Names
US Brand Name
Nilotinib is used to treat Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in adults and children who are newly diagnosed. It is also given to adults and children with Ph+ CML in chronic phase (CP) or accelerated phase (AP) who have taken other medicines (eg, imatinib, tyrosine-kinase inhibitor) but did not work well. Leukemia is a type of cancer where the body makes too many abnormal white blood cells.
Nilotinib belongs to the general group of medicines known as antineoplastics or cancer medicines. It interferes with the growth of cancer cells, which are eventually destroyed. Since the growth of normal cells may also be affected by nilotinib, other effects will also occur. Some of these may be serious and must be reported to your doctor. Other effects may not be serious but may cause concern.
Before you begin treatment with nilotinib, you and your doctor should talk about the benefits this medicine will do as well as the possible risks of using it.
This medicine is available only with your doctor's prescription.
This product is available in the following dosage forms:
Portions of this document last updated: May 01, 2023
版权 © 2023 IBM Watson Health。保留所有权利。信息仅供终端用户使用，不得出售、重新分发或用于其他商业目的。